Table 1.
Comparison of characteristics before and after propensity score matching (PSM)
| Variable | Before PSM | p-value | After PSM | p-value | ||
|---|---|---|---|---|---|---|
| AS (%) | SOX (%) | AS (%) | SOX (%) | |||
| Gender | 0.0098 | 1.0000 | ||||
| Male | 29 (46.8) | 56 (69.1) | 29 (53.7) | 29 (53.7) | ||
| Female | 33 (53.2) | 25 (30.9) | 25 (46.8) | 25 (46.8) | ||
| Age | 0.3440 | 1.0000 | ||||
| ≤ 65 | 48 (77.4) | 56 (69.1) | 43 (79.6) | 43 (79.6) | ||
| > 65 | 14 (22.6) | 25 (30.9) | 11 (20.4) | 11 (20.4) | ||
| Ascites | 0.2177 | 1.0000 | ||||
| Without | 26 (41.9) | 25 (30.9) | 21 (38.9) | 20 (37.0) | ||
| With | 36 (58.1) | 56 (69.1) | 33 (61.1%) | 34 (63.0) | ||
| Lauren type | 0.0006 | 0.0172 | ||||
| Intestinal | 4 (6.5) | 26 (32.1) | 0.3169a | 4 (7.4) | 15 (27.8) | 0.5255b |
| Diffuse | 42 (67.7) | 35 (43.2) | 34 (63.0) | 24 (44.4) | ||
| Mixed | 16 (25.8) | 20 (24.7) | 16 (29.6) | 15 (27.8) | ||
| Cycles | 0.0290 | 0.2318 | ||||
| ≤ 3 | 9 (14.5) | 25 (30.9) | 8 (14.8) | 14 (25.9) | ||
| > 3 | 53 (85.5) | 56 (69.1) | 46 (85.2) | 40 (74.1) | ||
| Surgery | 0.6602 | 1.0000 | ||||
| Yes | 5 (8.1) | 5 (6.2) | 5 (9.3) | 5 (9.3) | ||
| No | 57 (91.9) | 76 (93.8) | 49 (90.7) | 49 (90.7) | ||
| Inhibitor | 0.4099 | 0.3750 | ||||
| Yes | 8 (12.9) | 7 (8.6) | 8 (14.8) | 5 (9.3) | ||
| No | 54 (87.1) | 74 (91.4) | 46 (85.2) | 49 (90.7) | ||
| HER2 | 0.7631 | 1.0000 | ||||
| Negative | 56 (90.3) | 75 (92.6) | 49 (90.7) | 49 (90.7) | ||
| Positive | 6 (9.7) | 6 (7.4) | 5 (9.3) | 5 (9.3) | ||
| Trastuzumabc | 1.0000 | 1.0000 | ||||
| No | 1 (16.7) | 1 (16.7) | 1 (20) | 1 (20) | ||
| Yes | 5 (83.3) | 5 (83.3) | 4 (80) | 4 (80) | ||
| Total | 62 (100) | 81 (100) | 54 (100) | 54 (100) | ||
ap-value between diffuse and mixed lauren type before PSM
bp-value between diffuse and mixed lauren type after PSM
ctrastuzumab in HER2 positive patients; Surgery, palliative surgery during or after first line chemotherapy; Inhibitor, checkpoint inhibitor